|
US5087617A
(en)
|
1989-02-15 |
1992-02-11 |
Board Of Regents, The University Of Texas System |
Methods and compositions for treatment of cancer using oligonucleotides
|
|
US5248671A
(en)
|
1989-02-15 |
1993-09-28 |
Board Of Regents, The University Of Texas System |
Methods and compositions for treatment of cancer using oligonucleotides
|
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
|
US6111094A
(en)
|
1990-08-14 |
2000-08-29 |
Isis Pharmaceuticals Inc. |
Enhanced antisense modulation of ICAM-1
|
|
US6015886A
(en)
*
|
1993-05-24 |
2000-01-18 |
Chemgenes Corporation |
Oligonucleotide phosphate esters
|
|
ATE164515T1
(de)
|
1993-11-05 |
1998-04-15 |
Amgen Inc |
Herstellung von liposomen und verfahren zur substanzverkapselung
|
|
US5855911A
(en)
*
|
1995-08-29 |
1999-01-05 |
Board Of Regents, The University Of Texas System |
Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
|
|
US7309692B1
(en)
|
1996-07-08 |
2007-12-18 |
Board Of Regents, The University Of Texas System |
Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
|
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
|
US6977244B2
(en)
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
|
US7262173B2
(en)
|
1997-03-21 |
2007-08-28 |
Georgetown University |
Chemosensitizing with liposomes containing oligonucleotides
|
|
US7704962B1
(en)
|
1997-10-03 |
2010-04-27 |
Board Of Regents, The University Of Texas System |
Small oligonucleotides with anti-tumor activity
|
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
|
US20030180789A1
(en)
|
1998-12-30 |
2003-09-25 |
Dale Roderic M.K. |
Arrays with modified oligonucleotide and polynucleotide compositions
|
|
WO2000040592A1
(en)
|
1998-12-30 |
2000-07-13 |
Oligos Etc. Inc. |
Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof
|
|
US7098192B2
(en)
*
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
|
WO2001026625A2
(en)
|
1999-10-08 |
2001-04-19 |
Alza Corp |
Neutral-cationic lipid for nucleic acid and drug delivery
|
|
US20050186264A1
(en)
|
2000-10-12 |
2005-08-25 |
Kiani Mohammad F. |
Targeting drug/gene carriers to irradiated tissue
|
|
US7060690B2
(en)
|
2001-01-22 |
2006-06-13 |
Genta Incorporated |
Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof
|
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
|
WO2003062421A1
(en)
|
2002-01-17 |
2003-07-31 |
The University Of British Columbia |
Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
|
|
US20030147813A1
(en)
|
2002-02-07 |
2003-08-07 |
John Lyons |
Method for treating chronic myelogenous leukemia
|
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
AU2003295600A1
(en)
*
|
2002-11-14 |
2004-06-15 |
Dharmacon, Inc. |
Functional and hyperfunctional sirna
|
|
US8969314B2
(en)
|
2003-07-31 |
2015-03-03 |
Regulus Therapeutics, Inc. |
Methods for use in modulating miR-122a
|
|
EP1670955A2
(en)
*
|
2003-09-22 |
2006-06-21 |
Rosetta Inpharmatics LLC. |
Synthetic lethal screen using rna interference
|
|
ES2636470T3
(es)
*
|
2004-04-09 |
2017-10-05 |
Genomic Health, Inc. |
Marcadores de expresión génica para predecir la respuesta a la quimioterapia
|
|
US7915399B2
(en)
*
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
US20080171718A1
(en)
|
2006-11-08 |
2008-07-17 |
Brown Bob D |
Methods and Compositions for Treating Cancer Using BCL-2 Antisense Oligomers, Tyrosine Kinase Inhibitors, and Chemotherapeutic Agents
|
|
CA2704853C
(en)
*
|
2007-11-06 |
2017-08-15 |
Eugen Uhlmann |
Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
|
|
CN102239178B
(zh)
|
2008-10-02 |
2017-06-23 |
Vib研究所 |
抑制PlGF以治疗费城染色体阳性白血病
|
|
WO2012024396A2
(en)
|
2010-08-17 |
2012-02-23 |
Rutgers, The State University Of New Jersey |
Compositions and methods for delivering nucleic acid molecules and treating cancer
|
|
WO2012112730A2
(en)
|
2011-02-15 |
2012-08-23 |
Merrimack Pharmaceuticals, Inc. |
Compositions and methods for delivering nucleic acid to a cell
|
|
US9322015B2
(en)
|
2011-03-09 |
2016-04-26 |
The Brigham And Women's Hospital, Inc. |
Methods of using microRNA-26a to promote angiogenesis
|
|
CN103562215B
(zh)
*
|
2011-04-01 |
2017-04-26 |
埃西斯药品公司 |
信号转导及转录激活蛋白3(stat3)表达的调节
|
|
EP3003275B1
(en)
|
2013-06-03 |
2020-11-18 |
Bar-Ilan University |
Liposomes for modulating wiskott-aldrich syndrome protein
|
|
US10182988B2
(en)
|
2013-12-03 |
2019-01-22 |
Northwestern University |
Liposomal particles, methods of making same and uses thereof
|
|
CA2982205A1
(en)
|
2015-04-10 |
2016-10-13 |
David W. Andrews |
Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
|
|
EP3362563A1
(en)
|
2015-10-14 |
2018-08-22 |
Bio-Path Holdings, Inc. |
P-ethoxy nucleic acids for liposomal formulation
|
|
JP7132911B2
(ja)
|
2016-09-16 |
2022-09-07 |
バイオ－パス ホールディングス， インコーポレイテッド |
リポソームアンチセンスオリゴヌクレオチドとの併用療法
|
|
EP3592841B1
(en)
|
2017-03-09 |
2024-02-14 |
Thomas Jefferson University |
Compositions for treating cancers using antisense
|
|
IL269608B2
(en)
|
2017-04-19 |
2024-06-01 |
Bio Path Holdings Inc |
Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease
|
|
WO2018195250A1
(en)
|
2017-04-19 |
2018-10-25 |
Bio-Path Holdings, Inc. |
P-ethoxy nucleic acids for igf-1r inhibition
|
|
EP3612160A4
(en)
|
2017-04-19 |
2021-01-20 |
Bio-Path Holdings, Inc. |
P-ETHOXY NUCLEIC ACIDS FOR BCL2 INHIBITION
|
|
JP2020517645A
(ja)
|
2017-04-19 |
2020-06-18 |
バイオ−パス ホールディングス， インコーポレイテッド |
Ｉｇｆ−１ｒ阻害のためのｐ−エトキシ核酸
|
|
WO2020198587A1
(en)
|
2019-03-28 |
2020-10-01 |
Thomas Jefferson University |
Methods for treating cancers using antisense
|
|
CN112830354A
(zh)
|
2019-11-22 |
2021-05-25 |
富泰华工业（深圳）有限公司 |
基于区块链系统的电梯调度系统、装置、方法及存储介质
|